Company intelligence / Profile preview

Novapharm

Ownership: Private
Development stage: Phase 3

Overview

NovaPharm Therapeutics focuses on developing new treatments for pain management and metabolic diseases. The company has advanced lead compounds through preclinical and early clinical development but does not publicly disclose detailed results or compound names.

Therapeutic areas: Metabolic DisordersNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

neridronic acid

Phase 3

Indications: Complex regional pain syndrome

Beyond the preview

Go deeper on Novapharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novapharm.

Explore the full profile